Cellectis
Why Robinhood?
You can watch Cellectis and buy or sell other stocks, ETFs, and their options commission-free!About CLLS
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J.
CLLS Key Statistics
Stock Snapshot
The current Cellectis(CLLS) stock price is $3.97, with a market capitalization of 286.93M. The stock trades at a price-to-earnings (P/E) ratio of -12.18.
During the trading session on 2025-12-17, Cellectis(CLLS) shares reached a daily high of $4.09 and a low of $3.89. At a current price of $3.97, the stock is +2.1% higher than the low and still -2.9% under the high.
Trading activity shows a volume of 77.63K, compared to an average daily volume of 116.9K.
The stock's 52-week range extends from a low of $1.10 to a high of $5.48.
The stock's 52-week range extends from a low of $1.10 to a high of $5.48.
CLLS News
Shares of Cellectis S.A. (NASDAQ:CLLS) tanked on Tuesday after Allogene Therapeutics Inc. (NASDAQ:ALLO) cited a favorable arbitration outcome for partner Servie...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
Allogene Therapeutics (ALLO) noted the favorable outcome for Servier in its arbitration with Cellectis (CLLS) as it relates to cemacabtagene ansegedleucel. This...
Analyst ratings
75%
of 8 ratingsMore CLLS News
Cellectis (CLLS) announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Re...